Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Anat Idan-Feldman"'
Autor:
Anat Idan-Feldman, Yulie Schirer, Eleni Polyzoidou, Olga Touloumi, Roza Lagoudaki, Nikolaos C. Grigoriadis, Illana Gozes
Publikováno v:
Neurobiology of Disease, Vol 44, Iss 3, Pp 327-339 (2011)
Aims: Central nervous system complications including cognitive impairment are an early manifestation of diabetes mellitus, also evident in animal models. NAP (generic name, davunetide), a neuroprotective peptide was tested here for its ability to pre
Externí odkaz:
https://doaj.org/article/2708ce2522ae41d5b1c9ce5497b7b336
Publikováno v:
International Journal of Alzheimer's Disease, Vol 2012 (2012)
The peptide drug candidate NAP (davunetide) has demonstrated protective effects in various in vivo and in vitro models of neurodegeneration. NAP was shown to reduce tau hyperphosphorylation as well as to prevent caspase-3 activation and cytochrome-3
Externí odkaz:
https://doaj.org/article/4c56cdd5e40d4c4c86e46f60965a97da
Autor:
Eleni Polyzoidou, Olga Touloumi, Illana Gozes, Roza Lagoudaki, Nikolaos Grigoriadis, Anat Idan-Feldman, Yulie Schirer
Publikováno v:
Neurobiology of Disease, Vol 44, Iss 3, Pp 327-339 (2011)
Aims Central nervous system complications including cognitive impairment are an early manifestation of diabetes mellitus, also evident in animal models. NAP (generic name, davunetide), a neuroprotective peptide was tested here for its ability to prev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6b4da7eadd1526dd83150c7aa1a8ac3
http://www.sciencedirect.com/science/article/pii/S0969996111002488
http://www.sciencedirect.com/science/article/pii/S0969996111002488
Publikováno v:
Journal of molecular neuroscience : MN. 59(2)
NAPVSIPQ (NAP) and all D-amino acid SALLRSIPA (D-SAL) are neuroprotective peptides derived from activity-dependent neuroprotective protein (ADNP) and activity-dependent neurotrophic factor (ADNF), respectively. Both proteins were shown to protect aga
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::178091135a5d6bd62d82a8b08dbf2887
https://pubmed.ncbi.nlm.nih.gov/26816081
https://pubmed.ncbi.nlm.nih.gov/26816081
Publikováno v:
Journal of molecular neuroscience : MN. 52(1)
We set out to identify NAP (davunetide) analogs, providing neuroprotection and reducing tau pathology, specifically addressing protection against protein misfolding. NAP (NAPVSIPQ, intranasal formulation AL-108) is a drug candidate that (1) had a sta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc8fd2ee24dc1ac5f456cdb0730d55c0
https://pubmed.ncbi.nlm.nih.gov/24458740
https://pubmed.ncbi.nlm.nih.gov/24458740
Publikováno v:
International Journal of Alzheimer's Disease, Vol 2012 (2012)
International Journal of Alzheimer's Disease
International Journal of Alzheimer's Disease
The peptide drug candidate NAP (davunetide) has demonstrated protective effects in variousin vivoandin vitromodels of neurodegeneration. NAP was shown to reduce tau hyperphosphorylation as well as to prevent caspase-3 activation and cytochrome-3 rele
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70de8ae3429eda60e3a71fe030469f3c
Publikováno v:
Journal of Molecular Neuroscience; Jan2014, Vol. 52 Issue 1, p1-9, 9p